Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 30, 2019 - Issue 8
Submit an article Journal homepage
370
Views
1
CrossRef citations to date
0
Altmetric
Psoriasis and dermatitis

Institute for clinical and economic review (ICER) psoriasis update 2018: what it means for dermatologists treating moderate-to-severe plaque psoriasis

Erica B. LeeJohn A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii;
,
Deeti J. PithadiaMedical College of Georgia, Augusta University, Augusta, GA, USA;
,
Kelly A. ReynoldsCollege of Medicine, University of Cinicinnati, Cincinnati, OH, USA;
&
Jashin J. WuDermatology Research and Education Foundation, Irvine, CA, USACorrespondence[email protected]
Pages 772-774 | Received 10 Dec 2018, Accepted 13 Jan 2019, Published online: 12 Feb 2019

References

  • Banken R, Agboola F, Fazioli K et al. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value – condition update. Boston, MA: Institute for Clinical and Economic Review; 2018.
  • Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med. 1998;13:716–717.
  • Feldman SR, Burudpakdee C, Gala S, et al. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2014;14:685–703.
  • James SM, Hill DE, Feldman SR. Costs of common psoriasis medications, 2010–2014. J Drugs Dermatol. 2016;15:305–308.
  • Levin AA, Gottlieb AB, Au SC. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. J Drugs Dermatol. 2014;13: 848–853.
  • Mauskopf J, Samuel M, McBride D, et al. Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines. Pharmacoeconomics. 2014;32:395–409.
  • Abdelnabi M, Patel A, Rengifo-Pardo M, et al. Insurance coverage of biologics for moderate-to-severe psoriasis: a retrospective, observational 5-year chart review. Am J Clin Dermatol. 2016;17:421–424.
  • Dolgin E. First eczema biologic debuts but price could restrict use. Nat Biotechnol. 2017;35:391–392.
  • Institute for Clinical and Economic Review. Dupilumab and crisaborole for Atopic dermatitis: effectiveness and value. Evidence Report. May 12, 2017. https://icer-review.org/wp-content/uploads/2016/10/MWCEPAC_ATOPIC_EVIDENCE_REPORT_051217.pdf Accessed 1 Nov 2018.
  • Kuznik A, Bego-Le-Baggouse G, Eckert L, et al. Economic evaluation of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Dermatol Ther (Heidelb). 2017;7:493–505.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.